Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Reducing recurrence of advanced melanoma with pembrolizumab

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 4079

Prof Alex Eggermont - Paris-Sud University, Paris, France

Prof Eggermont speaks with ecancer at AACR 2018 about reducing recurrence of advanced melanoma with pembrolizumab.

In the KEYNOTE-054 trial, a one year course of 200mg pembrolizumab every 3 weeks improved the 12 month recurrence free survival rate from 61% on placebo to 75%.

For more on the trial results, read here or watch Prof Eggermont present the findings in a press session here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation